MeiraGTx Holdings Investor Relations Material

MeiraGTx Holdings plc is a clinical-stage gene therapy company dedicated to developing potentially curative treatments for patients suffering from serious diseases. The company's research and development efforts are currently concentrated on six clinical programs, which include treatments for four types of ocular diseases, a salivary gland condition, and Parkinson’s disease. MeiraGTx's approach is particularly focused on areas with significant unmet medical needs, such as diseases of the eye, salivary gland, and central nervous system. The company is headquartered in New York and London, and its shares are listed on the Nasdaq.